Archive
Home / Media Centre / Archive
Here you can find the archive of all Press Releases prior to 2022
Filter by date:
Showing 1107 press releases before 2022
-
Farxiga met primary endpoint in landmark Phase III DAPA-HF trial for the treatment of patients with heart failure
-
Lynparza Phase III PAOLA-1 trial met primary endpoint as 1st-line maintenance treatment with bevacizumab for advanced ovarian cancer
-
Calquence granted US Breakthrough Therapy Designation for chronic lymphocytic leukaemia
-
Tagrisso significantly improves overall survival in the Phase III FLAURA trial for 1st-line EGFR-mutated non-small cell lung cancer
-
Lynparza Phase III PROfound trial in HRR* mutation-selected metastatic castration-resistant prostate cancer met primary endpoint
-
Forxiga label updated in the EU in type-2 diabetes
-
H1 2019 Results
-
Update on US regulatory decision for Farxiga in type-1 diabetes
-
Imfinzi granted US Orphan Drug Designation for small cell lung cancer
-
Forxiga receives positive EU CHMP opinion for DECLARE-TIMI 58 cardiovascular outcomes data
Latest articles and press releases
All of our latest press releases and articles are available to explore
